Aria F. Olumi, M.D.
Aria F. Olumi, M.D.
Beth Israel Deaconess Medical Center
Verified email at
Cited by
Cited by
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
AF Olumi, GD Grossfeld, SW Hayward, PR Carroll, GR Cunha, P Hein, ...
Breast Cancer Research 2 (1), 1-1, 2000
5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes
WM Rideout, GA Coetzee, AF Olumi, PA Jones
Science 249 (4974), 1288-1290, 1990
Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder
AF Olumi, YC Tsai, PW Nichols, DG Skinner, DR Cain, LI Bender, ...
Cancer research 50 (21), 7081-7083, 1990
MR imaging of renal masses: correlation with findings at surgery and pathologic analysis
I Pedrosa, MR Sun, M Spencer, EM Genega, AF Olumi, WC Dewolf, ...
Radiographics 28 (4), 985-1003, 2008
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation
PA Gameiro, J Yang, AM Metelo, R Pérez-Carro, R Baker, Z Wang, ...
Cell metabolism 17 (3), 372-385, 2013
Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy
IF San Francisco, WC DeWOLF, S Rosen, M Upton, AF Olumi
The Journal of urology 169 (1), 136-140, 2003
Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage
CH Spruck, WM Rideout, AF Olumi, PF Ohneseit, AS Yang, YC Tsai, ...
Cancer research 53 (5), 1162-1166, 1993
Role of chromosome 9 in human bladder cancer
N Miyao, YC Tsai, SP Lerner, AF Olumi, CH Spruck, M Gonzalez-Zulueta, ...
Cancer research 53 (17), 4066-4070, 1993
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism
SM Fendt, EL Bell, MA Keibler, SM Davidson, GJ Wirth, B Fiske, ...
Cancer research 73 (14), 4429-4438, 2013
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-κB agonist Card9 by CK2
H Yang, YA Minamishima, Q Yan, S Schlisio, BL Ebert, X Zhang, L Zhang, ...
Molecular cell 28 (1), 15-27, 2007
Persistent c-FLIP (L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand–mediated apoptosis in prostate cancer
X Zhang, TG Jin, H Yang, WC DeWolf, R Khosravi-Far, AF Olumi
Cancer research 64 (19), 7086-7091, 2004
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer
AA Aizer, JJ Paly, AL Zietman, PL Nguyen, CJ Beard, SK Rao, ID Kaplan, ...
Journal of Clinical Oncology 30 (25), 3071-3076, 2012
Metformin use and prostate cancer risk
MA Preston, AH Riis, V Ehrenstein, RH Breau, JL Batista, AF Olumi, ...
European urology 66 (6), 1012-1020, 2014
Personalized medicine for the management of benign prostatic hyperplasia
SK Bechis, AG Otsetov, R Ge, AF Olumi
The Journal of urology 192 (1), 16-23, 2014
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations
L Li, L Zhang, X Zhang, Q Yan, YA Minamishima, AF Olumi, M Mao, ...
Molecular and cellular biology 27 (15), 5381-5392, 2007
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP (L)
W Li, X Zhang, AF Olumi
Cancer research 67 (5), 2247-2255, 2007
The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection
JO Ung, IF San Francisco, MM Regan, WC DeWOLF, AF Olumi
The Journal of urology 169 (1), 130-135, 2003
Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system
F Dong, C Wang, AB Farris, S Wu, H Lee, AF Olumi, WS McDougal, ...
The American journal of surgical pathology 36 (6), 838-843, 2012
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells
X Zhang, L Zhang, H Yang, X Huang, H Otu, TA Libermann, WC DeWolf, ...
Cancer research 67 (19), 9425-9434, 2007
Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity
The Journal of urology 159 (5), 1437-1443, 1998
The system can't perform the operation now. Try again later.
Articles 1–20